The aim of the study is to recruit 30 patients who have been referred to Auerach Hematology Oncology Assoc. for the treatment of iron defeciency anemia with iv iron (Ferumoxytol 1020 mg) administered via infusion pump over 15 minutes.

To ascertain acute safety and tolerability of ferumoxytol during immediate post dosing observation period.

Assess additional safety profile and laboratory assessment at follow up visit and interim telephone follow up.

Ferumoxytol, a modified iron dextran, which allows the rapid administration of IV iron without free iron release, was approved for a 510 mg injection to be administered in not less than 17 seconds. Although this represents a felicitous treatment for patients who come frequently, such as dialysis and chemotherapy patients, multiple publications suggest that full dose replacement is usually at the 1000 mg level. No studies extant are available with this dosing schedule for ferumoxytol. In this trial, iron deficient patients with hemoglobin levels of <11.0 grams per deciliter will be consented to received 1020 mg (two 510 mg vials) of ferumoxytol in 15 minutes. Vital signs will be performed at 5, 10, 15, 30 and 60 minutes. Followup phone calls for any clinical adverse events will be made at 24-48 hours and one week after administration. At four weeks follow-up hematologic and serologic (iron parameters) will be made along with a physician visit.

Inclusion Criteria:

• Iron deficiency anemia intolerant of or failure to respond to oral iron or condition where oral iron is known to be ineffective or harmful.
• Subject must be able to be contacted at 24-48 hours after dose and come for followup at four weeks.
• Subject must be capable of understanding informed consent
• No other form of iron may be taken within four weeks of consent or for four weeks after treatment

Exclusion Criteria:

• History of hypersensitivity to ferumoxytol.
• Imminent dialysis.
• Anemia due to other etiology.
• Parenteral iron within 4 weeks of consent.
• Pregnancy.
• Erythropoiesis stimulating agent within 30 days of consent.
• Other illness that would interfere with participation or understanding of trial.
• Major surgery planned within four weeks of consent.

8 weeks from treatment day

Patients were observed for one hour after administration. Telephone calls were made at 24 and 48 hours and 7 days for delayed AEs. Follow visits in the office occurred at 4 and 8 weeks.